Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saracatinib plus weekly paclitaxel in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer
ISRCTN32163062Phase 3Completed
- Sponsor
- University College London
- Start
- Nov 2010
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Saracatinib + weekly paclitaxel with Placebo + weekly paclitaxel (2 arms). Primary endpoint: Six-month progression-free survival. Started Nov 2010; status: completed.
02
Drugs
saracatinibpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on ISRCTN32163062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN32163062.